FDA Approved Products
6,646 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
CIMDUO
lamivudine and tenofovir disoproxil fumarate
Peak
Viatris (2)
ORAL · TABLET
combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult
2018
NDA30/100
CINOBAC
cinoxacin
LOE Approaching
Eli Lilly and Company
ORAL · CAPSULE
1980
SMNDA30/100
CINTICHEM TECHNETIUM 99M HEDSPA
technetium tc-99m etidronate kit
LOE Approaching
INJECTION · INJECTABLE
1976
NDA30/100
CIPRO
ciprofloxacin
LOE Approaching
Bayer
INJECTION · INJECTABLE
infections caused by susceptible isolates of the designated microorganisms in the specific condition listed below: Acute Otitis Media (AOM) in pediatric patients (age 6 monthsolder) with tympanostomy tubes due to Staphylococcus aureus+4
1990
SMNDA30/100
CIPRO
ciprofloxacin hydrochloride
LOE Approaching
Bayer
ORAL · TABLET
plagueincluding pneumonic+38
1987
NDA30/100
CIPRO HC
ciprofloxacin hydrochloride and hydrocortisone
LOE Approaching
Novartis
OTIC · SUSPENSION/DROPS
acute otitis externa in adultone year+4
1998
NDA30/100
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER
ciprofloxacin
LOE Approaching
Bayer
INJECTION · INJECTABLE
infections caused by susceptible isolates of the designated microorganisms in the specific condition listed below: Acute Otitis Media (AOM) in pediatric patients (age 6 monthsolder) with tympanostomy tubes due to Staphylococcus aureus+4
1990
SMNDA30/100
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
ciprofloxacin
LOE Approaching
R-Pharm US
INJECTION · INJECTABLE
infections caused by susceptible isolates of the designated microorganisms in the specific condition listed below: Acute Otitis Media (AOM) in pediatric patients (age 6 monthsolder) with tympanostomy tubes due to Staphylococcus aureus+4
1990
SMNDA30/100
CIPRO XR
ciprofloxacin; ciprofloxacin hydrochloride
LOE Approaching
R-Pharm US
ORAL · TABLET, EXTENDED RELEASE
infections caused by susceptible isolates of the designated microorganisms in the specific condition listed below: Acute Otitis Media (AOM) in pediatric patients (age 6 monthsolder) with tympanostomy tubes due to Staphylococcus aureus+4
2003
NDA30/100
CIPRO XR
ciprofloxacin; ciprofloxacin hydrochloride
LOE Approaching
Bayer
ORAL · TABLET, EXTENDED RELEASE
infections caused by susceptible isolates of the designated microorganisms in the specific condition listed below: Acute Otitis Media (AOM) in pediatric patients (age 6 monthsolder) with tympanostomy tubes due to Staphylococcus aureus+4
2002
NDA30/100
CIPRODEX
ciprofloxacin and dexamethasone
LOE Approaching
Novartis
OTIC · SUSPENSION/DROPS
infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: • Acute Otitis Media (AOM) in pediatric patients (age 6 monthsolder) with tympanostomy tubes due to Staphylococcus aureus+4
2003
NDA30/100
CIS-MDP
tc 99m medronate
LOE Approaching
PharmaIN
INJECTION · INJECTABLE
1979
NDA30/100
CIS-PYRO
technetium tc99m pyrophosphate
LOE Approaching
PharmaIN
INJECTION · INJECTABLE
1987
NDA30/100
CISPLATIN
cisplatin
LOE Approaching
R-Pharm US
INJECTION · INJECTABLE
advanced testicular canceradvanced ovarian cancer+2
1978
NDA30/100
CITALOPRAM HYDROBROMIDE
citalopram hydrobromide
LOE Approaching
ORALLY DISINTEGRATING · TABLET
major depressive disorder (MDD) in adults ( )
2005
NDA30/100
CITALOPRAM HYDROBROMIDE
citalopram
Peak
Almatica Pharma
ORAL · CAPSULE
Major Depressive Disorder (MDD) in adults
2022
NDA30/100
CITANEST
prilocaine hydrochloride
LOE Approaching
AstraZeneca
INJECTION · INJECTABLE
1965
NDA30/100
CITANEST FORTE
epinephrine bitartrate; prilocaine hydrochloride
LOE Approaching
AstraZeneca
INJECTION · INJECTABLE
1965
NDA30/100
CITANEST FORTE DENTAL
epinephrine bitartrate; prilocaine hydrochloride
LOE Approaching
INJECTION · INJECTABLE
1965
NDA30/100
CITANEST PLAIN
prilocaine hydrochloride
LOE Approaching
AstraZeneca
INJECTION · INJECTABLE
1965
NDA30/100
CITANEST PLAIN DENTAL
prilocaine hydrochloride
LOE Approaching
INJECTION · INJECTABLE
1965
NDA30/100
CLAFORAN
cefotaxime sodium
LOE Approaching
INJECTION · INJECTABLE
1981
NDA30/100
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER
cefotaxime sodium
LOE Approaching
INJECTION · INJECTABLE
1985
NDA30/100
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
cefotaxime sodium
LOE Approaching
INJECTION · INJECTABLE
1985
NDA30/100